Steve Pacelli
CEO @ Obalon Therapeutics
San Diego, United States
Steve Pacelli is a Series A investor at Obalon Therapeutics in San Diego focused on Medical Device and Medical. More than 25 years of medical technology experience, including serving as CEO of DexCom, Inc., Senior Vice President and President Vascular for Medtronic, Inc., and Vice President of Marketing for Arterial Vascular Engineering.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Steve Pacelli invests in
Stages Steve Pacelli invests in
Countries Steve Pacelli invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $2.5M–$13M
Investment Focus
Industry
- Medical Device 2 (100%)
- Medical 1 (50%)
- mHealth 1 (50%)
- Oncology 1 (50%)
- Wearables 1 (50%)
Country
- Ireland 1 (50%)
- United States 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Luminate
|
Luminate is an oncology-focused healthtech and tech-enabled services company that partners with payers, providers, and people with cancer to reduce the cost of cancer care while improving quality of life and outcomes for patients. The company offers a portfolio of services and technologies that enable home-based cancer treatment, adverse eventmonitoring, and prevention of drug-induced side effects. | $2.5M / Series A / Dec 04, 2024 | |
Epitel
|
Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection. | $12.5M / Series A / Feb 16, 2022 |
Co-Investors
About Obalon Therapeutics
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize the treatment of chronicdisease. As a company, they believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.It was founded in 2008.
Obalon Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Steve Pacelli
CEO
|
|||
|
Amy Vandenberg
Vice President of Regulatory Affairs
|
|||
Bart Bandy
President of International
|
|||
|
Mark Brister
VP of R&D
|
|||
Nooshin Hussainy
Chief Financial Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Steve Pacelli invest in?
Steve Pacelli invests primarily in Medical Device, Medical and mHealth startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Steve Pacelli's check size?
Steve Pacelli typically joins rounds of $2.5M–$13M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Steve Pacelli participates in.
How do I contact Steve Pacelli?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Steve Pacelli last invest?
The most recent investment recorded for Steve Pacelli closed in Dec 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
